Experience of a Strategy Including CYP2C19 Preemptive Genotyping Followed by Therapeutic Drug Monitoring of Voriconazole in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Many factors have been described to contribute to voriconazole (VCZ) interpatient variability in plasma concentrations, especially CYP2C19 genetic variability. In 2014, Hicks et al. presented data describing the correlation between VCZ plasma concentrations and CYP2C19 diplotypes in immunocompromise...

Descripción completa

Detalles Bibliográficos
Autores principales: García-García, Irene, Dapía, Irene, Montserrat, Jaime, Martinez de Soto, Lucía, Bueno, David, Díaz, Lucía, Queiruga, Javier, Rodriguez Mariblanca, Amelia, Guerra-García, Pilar, Ramirez, Elena, Frías, Jesus, Pérez Martínez, Antonio, Carcas-Sansuan, Antonio J., Borobia, Alberto M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563584/
https://www.ncbi.nlm.nih.gov/pubmed/34744712
http://dx.doi.org/10.3389/fphar.2021.717932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563584/
https://www.ncbi.nlm.nih.gov/pubmed/34744712
http://dx.doi.org/10.3389/fphar.2021.717932

Ejemplares similares